Geneva, Switzerland and Boston, MA – April 16, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
Tag: 2018
ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018
Geneva, Switzerland and Boston, MA – March 26, 2018– ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials Key 2018 Clinical Milestones…
Q4 2017 ObsEva SA Earnings Conference Call
ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
Geneva, Switzerland and Boston, MA – March 2, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Oral administration of OBE022 shows favorable safety and results in predictable exposureNon-clinical results of OBE022 for PTL demonstrating fetal safety…
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
The WHO considers infertility a global public health issue affecting 186 million people, and only 1 in 4 ART treatments…
ObsEva Investor Conference Call
ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
Geneva, Switzerland and Boston, MA – February 23, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…